Login / Signup

Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.

Julie Ryan WolfAnita ChenJill WieserBrad JohnsonLauren BaughmanGayin LeeEleanor PopeAbigail FrancoTanzy LoveLisa A Beck
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Our results demonstrated that topical treatment for 12 weeks was more beneficial than 6 weeks, with TAC improving more PROs than CRIS. Future trials should implement PROs to fully understand the impact of AD treatments.
Keyphrases
  • atopic dermatitis
  • gestational age
  • case report
  • current status
  • type diabetes
  • metabolic syndrome
  • wound healing
  • glycemic control